

## Pharmacy and Therapeutics Committee

Virtual Meeting

June 18, 2024

12:00 PM - 5:00 PM

Zoom Registration Link - [AHCCCS P&T Zoom Registration](#)

Time	Topic
12:00 PM	<b>Welcome and Introductions:</b> Suzanne Berman, RPH, AHCCCS Pharmacy Director
12:10 PM	<b>Minutes Review and Vote - P&amp;T January 24, 2024:</b> Suzanne Berman, RPH, AHCCCS Pharmacy Director
12:15 PM	<b>Retrospective Drug Utilization Review Proposals -</b> Amanda Kiriakopoulos, PharmD, OptumRx
12:30 PM	<b>Conflict of Interest Training – Nicole Fries</b>
1:00 PM	<p><b>Seventeen Supplemental Rebate Drug Class:</b> Clinical review by Hind Douiki, PharmD, Magellan</p> <ol style="list-style-type: none"> <li>1. <b>Analgesics, Long-Acting Narcotics</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>2. <b>Antibiotics, Inhaled, Other</b> <ol style="list-style-type: none"> <li>a. Written Public Testimony:                             <ol style="list-style-type: none"> <li>i. Michelle Ratkiewicz</li> </ol> </li> </ol> </li> <li>3. <b>Antimigraine Agents, Other</b> <ol style="list-style-type: none"> <li>a. Oral Public Testimony:                             <ol style="list-style-type: none"> <li>i. David Gross</li> <li>ii. Mandeep Sohal</li> </ol> </li> </ol> </li> <li>4. <b>Antipsychotics, Atypical Long-Acting Injectables</b> <ol style="list-style-type: none"> <li>a. Oral Public Testimony:                             <ol style="list-style-type: none"> <li>i. Kenneth Berry</li> <li>ii. Emanga Ekinde</li> <li>iii. Matt John</li> <li>iv. Mandeep Sohal</li> </ol> </li> <li>b. Written Public Testimony                             <ol style="list-style-type: none"> <li>i. Casey Hollingsworth</li> <li>ii. Monica Benavidez</li> </ol> </li> </ol> </li> </ol>

**5. Antipsychotics, Oral Atypical 2<sup>nd</sup> Generation Agents**

- a. Oral Public Testimony:
  - i. Jazmin Acosta
  - ii. Kenneth Berry
  - iii. Heather Freml
  - iv. Shuntelle Hawk
  - v. Matt John
  
- b. Written Public Testimony:
  - i. Lori Parker
  - ii. Samantha Swartz
  - iii. Devin Wengert

**6. COPD Agents**

- a. Public Testimony: None

**7. Cytokine and CAM Antagonists**

- a. Oral Public Testimony:
  - i. Heather Freml
  - ii. Shirley Quach
  - iii. Mandeep Sohal

**8. Glucagon Agents**

- a. Oral Public Testimony:
  - i. Rachel Shubitz
- b. Written Public Testimony:

**9. Glucocorticoids, Inhaled**

- a. Public Testimony:

**10. Growth Hormone**

- a. Oral Public Testimony:
  - i. Dena Bondugji
  - ii. Tracy Maravilla
  - iii. Andrea Chamberlain
- b. Written Public Testimony
  - i. Anna Sandstrom

**11. Hepatitis C Agents**

- a. Oral Public Testimony:
  - i. Natalie Rose

**12. Hypoglycemics, Insulin and Related Agents**

- a. Written Public Testimony:
  - i. Tracie Neitzel
  - ii. Sreedevi Reddy

**13. Hypoglycemics, Incretin Mimetics/Enhancers**

- a. Oral Public Testimony:
  - i. Mohit Agarwal
  - ii. Lory Baraz
  - iii. Justen Caleca
- b. Written Public Testimony:
  - i. Edgardo R. Laurel

**14. Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma**

- a. Oral Public Testimony:
  - i. Hiten Patadia
- b. Written Public Testimony:
  - i. Ronald Mittel
  - ii. Heather O'Connell
  - iii. Colleen Schrant
  - iv. Lauren Weidman

**15. Opioid Dependence Treatments**

- a. Oral Public Testimony:
  - i. Emanga Ekinde – 2 drugs
  - ii. Sam Riega
  - iii. Michael Sucher
- b. Written Public Testimony:
  - i. Christa Cuellar
  - ii. Scott Havens
  - iii. Eric Lott

	<p><b>16. Pancreatic Enzyme Agents</b></p> <p>a. Oral Public Testimony:</p> <p><b>17. Stimulants and Related Agents</b></p> <p>a. Oral Public Testimony:</p> <p>i. Jia Li</p>
<b>3:00 PM</b>	<p><b>New Drug Reviews: Hind Douiki, PharmD, Magellan/Prime Therapeutics</b></p> <p>1. Rezdifra - Resmetiron</p> <p>a. Oral Public Testimony:</p> <p>i. William Lam</p>
<b>3:15 PM</b>	<b>Break &amp; Executive Session: Amber Small, PharmD, Magellan/Prime Therapeutics</b>
<b>4:30 PM</b>	<b>Public Therapeutic Class Votes: Hind Douiki/Umang Patel/Amber Small, PharmDs, Magellan/Prime Therapeutics</b>
<b>4:45 PM</b>	<b>Biosimilar Update: Suzi Berman</b>
<b>4:50 PM</b>	<p><b>Meeting Adjournment</b></p> <p><b>Future Meeting Dates:</b> October 15, 2024 January 25, 2025</p>